Skip to main content
eScholarship
Open Access Publications from the University of California

Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium.

  • Author(s): Wolpin, Brian M
  • Kraft, Peter
  • Xu, Mousheng
  • Steplowski, Emily
  • Olsson, Martin L
  • Arslan, Alan A
  • Bueno-de-Mesquita, H Bas
  • Gross, Myron
  • Helzlsouer, Kathy
  • Jacobs, Eric J
  • LaCroix, Andrea
  • Petersen, Gloria
  • Stolzenberg-Solomon, Rachael Z
  • Zheng, Wei
  • Albanes, Demetrius
  • Allen, Naomi E
  • Amundadottir, Laufey
  • Austin, Melissa A
  • Boutron-Ruault, Marie-Christine
  • Buring, Julie E
  • Canzian, Federico
  • Chanock, Stephen J
  • Gaziano, J Michael
  • Giovannucci, Edward L
  • Hallmans, Göran
  • Hankinson, Susan E
  • Hoover, Robert N
  • Hunter, David J
  • Hutchinson, Amy
  • Jacobs, Kevin B
  • Kooperberg, Charles
  • Mendelsohn, Julie B
  • Michaud, Dominique S
  • Overvad, Kim
  • Patel, Alpa V
  • Sanchéz, Maria-José
  • Sansbury, Leah
  • Shu, Xiao-Ou
  • Slimani, Nadia
  • Tobias, Geoffrey S
  • Trichopoulos, Dimitrios
  • Vineis, Paolo
  • Visvanathan, Kala
  • Virtamo, Jarmo
  • Wactawski-Wende, Jean
  • Watters, Joanne
  • Yu, Kai
  • Zeleniuch-Jacquotte, Anne
  • Hartge, Patricia
  • Fuchs, Charles S
  • et al.

Published Web Location

http://10.0.4.134/1055-9965.EPI-10-0751
No data is associated with this publication.
Abstract

Subjects with non-O ABO blood group alleles have increased risk of pancreatic cancer. Glycosyltransferase activity is greater for the A(1) versus A(2) variant, whereas O01 and O02 variants are nonfunctioning. We hypothesized: 1) A(1) allele would confer greater risk than A(2) allele, 2) protective effect of the O allele would be equivalent for O01 and O02 variants, 3) secretor phenotype would modify the association with risk.We determined ABO variants and secretor phenotype from single nucleotide polymorphisms in ABO and FUT2 genes in 1,533 cases and 1,582 controls from 12 prospective cohort studies. Adjusted odds ratios (OR) for pancreatic cancer were calculated using logistic regression.An increased risk was observed in participants with A(1) but not A(2) alleles. Compared with subjects with genotype O/O, genotypes A(2)/O, A(2)/A(1), A(1)/O, and A(1)/A(1) had ORs of 0.96 (95% CI, 0.72-1.26), 1.46 (95% CI, 0.98-2.17), 1.48 (95% CI, 1.23-1.78), and 1.71 (95% CI, 1.18-2.47). Risk was similar for O01 and O02 variant O alleles. Compared with O01/O01, the ORs for each additional allele of O02, A(1), and A(2) were 1.00 (95% CI, 0.87-1.14), 1.38 (95% CI, 1.20-1.58), and 0.96 (95% CI, 0.77-1.20); P, O01 versus O02 = 0.94, A(1) versus A(2) = 0.004. Secretor phenotype was not an effect modifier (P-interaction = 0.63).Among participants in a large prospective cohort consortium, ABO allele subtypes corresponding to increased glycosyltransferase activity were associated with increased pancreatic cancer risk.These data support the hypothesis that ABO glycosyltransferase activity influences pancreatic cancer risk rather than actions of other nearby genes on chromosome 9q34.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item